疑似子痫前期中血管生成标志物与新生儿结局的回顾性队列研究
该回顾性队列研究纳入162例疑似子痫前期孕妇的单胎新生儿,比较sFlt-1/PlGF比值≥85与<85两组的新生儿结局。调整 gestational age、子痫前期和新生儿性别后,比值≥85与小于胎龄儿、喂养不耐受、需肠外营养及住院时间延长显著相关。
要点
- sFlt-1/PlGF比值≥85与SGA风险增加独立相关(aOR=2.52)。
- 高比值组需肠外营养风险显著升高(aOR=11.19)。
- 比值升高与呼吸支持、肠外营养及住院时间延长相关。
核心结论
- 分娩前4周内母体sFlt-1/PlGF比值升高与小于胎龄儿、胃肠道并发症、肠外营养延长及住院时间延长显著相关。
研究设计与样本
- 回顾性队列研究,纳入香港一家三级中心2020年1月至2023年5月间162例疑似子痫前期孕妇的单胎新生儿,分娩前4周内检测sFlt-1/PlGF。
主要发现
- 调整 gestational age、子痫前期和新生儿性别后,sFlt-1/PlGF≥85与SGA(aOR=2.52,95%CI 1.12-5.60)、喂养不耐受(aOR=3.03,95%CI 1.01-9.09)、需肠外营养(aOR=11.19,95%CI 2.23-56.29)、肠外营养延长(aOR=6.92,95%CI 1.43-33.39)、住院超过7天(aOR=3.62,95%CI 1.20-10.87)和超过30天(aOR=7.04,95%CI 1.08-45.80)显著相关。
- 线性回归显示sFlt-1/PlGF比值与呼吸支持时间、肠外营养时间及住院时间显著相关。
关键数值与推荐
- sFlt-1/PlGF比值≥85定义为高风险组,<85为低风险组。
临床怎么用
- 对疑似子痫前期孕妇,分娩前4周内检测sFlt-1/PlGF比值有助于识别新生儿不良结局高风险者,比值≥85提示需加强新生儿监护。
局限性
- 回顾性设计、单中心、样本量162例,可能存在选择偏倚和混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFlt1) are two biomarkers associated with placental function and the sFlt-1/PlGF ratio is frequently used for risk assessment and prediction of preeclampsia in pregnancy. OBJECTIVE: To assess the association between elevated sFlt-1/PlGF ratio and adverse neonatal outcomes in pregnancies with suspected preeclampsia. DESIGN: Retrospective cohort study. SETTING: A tertiary centre in Hong Kong. POPULATION: 162 singleton neonates delivered between January 2020 and May 2023 from pregnancies complicated by suspected preeclampsia and sFlt-1/PlGF taken within 4 weeks before delivery. METHODS: Pregnant women with suspected preeclampsia were recruited with analysis of serum Flt-1 and PlGF. Neonatal outcomes were compared between neonates from pregnancies with sFlt-1/PlGF ratio ≥ 85 (high-risk group) and < 85 (low-risk group). MAIN OUTCOME MEASURES: Neonatal outcomes including growth, respiratory, gastrointestinal, and metabolic complications. RESULTS: Logistic regression analysis showed that after adjustment for gestational age, preeclampsia and newborn sex, sFlt-1/PlGF ratio ≥ 85 was significantly associated with small-for-gestation (SGA; aOR = 2.52, 95% C.I. = 1.12-5.60), feeding intolerance (aOR = 3.03, 95% C.I. = 1.01-9.09), need for parenteral nutrition (PN; aOR = 11.19, 95% C.I. = 2.23-56.29), prolonged PN (aOR = 6.92, 95% C.I. = 1.43-33.39), hospitalisation over 7 and 30 days (aOR = 3.62, 95% C.I. = 1.20-10.87 and aOR = 7.04, 95% C.I. = 1.08-45.80 respectively). Linear regression showed a significant association between sFlt-1/PlGF ratio and duration of respiratory support, PN and duration of hospital stay. CONCLUSIONS: An elevated maternal sFlt-1/PlGF ratio within 4 weeks of delivery is significantly associated with adverse neonatal outcomes including SGA, gastrointestinal complications, prolonged parenteral nutrition and prolonged hospitalisation.
引用
- Fung GPG, Lam HS, Chan KYY, et al. Angiogenic Biomarkers and Neonatal Outcomes in Suspected Preeclampsia: Retrospective Cohort Study. BJOG. 2025. PMID: 41355705. doi:10.1111/1471-0528.70104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。